(Q43129816)

14 November 2017

Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis (English)

1 reference

14 November 2017

1 reference

Daichi Inoue

1

1 reference

14 November 2017

Hiroshi Arima

2

1 reference

14 November 2017

Chiharu Kawanami

3

1 reference

14 November 2017

Yoko Takiuchi

4

1 reference

14 November 2017

Seiji Nagano

5

1 reference

14 November 2017

Takaharu Kimura

6

1 reference

14 November 2017

Sonoko Shimoji

7

1 reference

14 November 2017

Minako Mori

8

1 reference

14 November 2017

Sumie Tabata

9

1 reference

14 November 2017

Soshi Yanagita

10

1 reference

14 November 2017

Akiko Matsushita

11

1 reference

14 November 2017

Kenichi Nagai

12

1 reference

14 November 2017

Yukihiro Imai

13

1 reference

14 November 2017

Takayuki Takahashi

14

1 reference

14 November 2017

15 March 2010

1 reference

14 November 2017

Clinical Rheumatology

1 reference

14 November 2017

29

1 reference

14 November 2017

10

1 reference

14 November 2017

1195-1197

1 reference

Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression.

14 November 2017

1 reference

12 December 2020

Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment

1 reference

12 December 2020

Systemic amyloidosis and the gastrointestinal tract

1 reference

12 December 2020

Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy

1 reference

12 December 2020

Natural history and outcome in systemic AA amyloidosis

1 reference

12 December 2020

The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis

1 reference

12 December 2020

Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis.

1 reference

12 December 2020

Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein

1 reference

12 December 2020

Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis.

1 reference

12 December 2020

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

12 December 2020

Amyloidosis as a cause of death in patients with rheumatoid arthritis

1 reference

12 December 2020

Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis

1 reference

12 December 2020

Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis

1 reference

12 December 2020

10.1007/S10067-010-1422-6

Identifiers

DOI

1 reference

14 November 2017

1 reference